Herein, we presented a novel HER2 ADC, SHR-4602, which demonstrated good in vitro and in vivo anti-tumor activities and could overcome the resistance caused by HER2 ADC including DS-8201 analogue (synthesized using DS-8201 structure) and SHR-A1811 (composed of trastuzumab, a cleavable linker,...
M. et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol. Cancer Ther. 14, 692–703 (2015). Article Google Scholar Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and ...
Tokyo, Basking Ridge, NJ, and Munich– (March 27, 2018)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
Jhaveri K, Han H, Dotan E, Oh DY, Ferrario C, Tolcher A, et al. 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol. 2022;33:S74...
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N. Engl. J. Med.387, 9–20 (2022).A phase III trial that demonstrated the efficacy of the anti-HER2 ADC, trastuzumab deruxtecan, in HER2-low metastatic breast cancer. ...
HER2-targeting ADC trastuzumab deruxtecan or HER3-targeting ADC patritumab deruxtecan, using the same cleavable linker-payload system, demonstrated promising responsiveness in patients with HER2-positive CRC or EGFR-mutated NSCLC, respectively. The current manuscript presents an overview of the ...
Table 3. Selected ongoing studies of ADC in NSCLC with HER2 alterations. TrialPhaseDrugPatient selectionNHER2 alteration typePrimary endpointLocationEstimated Study Completion Date NCT04686305 Ib T-DXd;T-DXd + Durvalumab;T-DXd + Durvalumab + ChT; Part1: Second-line and third-line NSCLCPart2:Treat...
Netherlands) is a novel HER2-targeting ADC which has a ‘cleavable’ linker-duocarmycin payload, valine-citrulline-seco Duocarmycin hydroxyBenzamide Azaindole (vc-seco-DUBA), conjugated to trastuzumab. Impressive preclinical results of SYD985 antitumor activi- ty have been reported in breast cancer...
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation antibody-drug conjugates (ADC). A leading ADC...
ADC, antibody-drug conjugate; SDR: stable disease rate; w/, with; w/o, without; PFS, progression-free survival; T-DM1, Trastuzumab emtansine; SAE, serious adverse event; ECD, extracellular domain; BsAb, bispecific antibody; DCR: disease control rate (percentage of patients who achieved complet...